Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-120 in advanced solid tumors with FGFR aberrations
NL-OMON48846Phase 2Active, not recruiting
- Sponsor
- Taiho Oncology
- Start
- Jul 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of futibatinib in Nonhematologic neoplasms, cholangiocarcinoma (CCA), intrahepatic cholangiocarcinoma (ICC) and 3 more (9 arms), sponsored by Taiho Oncology. Primary endpoints: Objective response rate and Early progression-free rate. Started Jul 2019; status: active, not recruiting.
02
Drugs
futibatinib
03
Conditions
Nonhematologic neoplasmscholangiocarcinoma (CCA)intrahepatic cholangiocarcinoma (ICC)extrahepatic cholangiocarcinoma (eCCA)central nervous system primary tumor
Beyond the preview
Go deeper on NL-OMON48846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48846.